Hanmi Pharm Business Model

Hanmi Pharmaceutical Co., Ltd. primarily engages in the manufacturing and sales of pharmaceuticals, with key products including the combination antihypertensive 'Amosartan', the combination dyslipidemia treatment 'Rosuzet', the reflux esophagitis treatment 'Esomezol', the benign prostatic hyperplasia treatment 'Hanmi Tams Capsule', and the erectile dysfunction treatment 'PalPal Tab'. We are also committed to developing innovative new drugs through R&D.

Hanmi Fine Chemical Co., Ltd. is a specialized active pharmaceutical ingredient (API) company established in 1984.
Its main products are recognized for their excellent quality in the cephalosporin-based antibiotic market and the general API market. Notably, in 2006, it underwent an audit by the U.S. Food and Drug Administration (FDA) for its sterile API division. Furthermore, in 2007, a new API synthesis plant was completed, diversifying the product lineup beyond cephalosporins. This new plant also received cGMP certification from the US FDA, Germany's BSG, Australia's TGA, and Japan's PMDA. Currently, Hanmi Fine Chemical exports its products to over 40 countries worldwide, including numerous multinational pharmaceutical companies.

Beijing Hanmi Pharmaceutical Co., Ltd. was established in 1996 with investment from Hanmi Pharmaceutical Co., Ltd. Having grown into an independent pharmaceutical company capable of performing all aspects from pharmaceutical R&D to production and sales, Beijing Hanmi Pharmaceutical Co., Ltd. continues its steady growth. Its main products are the pediatric digestive supplement 'Mami Ai' and the cough and phlegm medicine 'Itanjing', along with over 20 other products including the adult gastrointestinal treatment 'Meichangan'.
Additionally, in 2022, it launched the combination antihypertensive 'Meiyaping' (Korean product name: Amosartan), and Beijing Hanmi Pharmaceutical Co., Ltd. is also leading global new drug development through R&D network synergy with Hanmi Pharmaceutical Co., Ltd. of Korea.